文献速递病毒性肝炎艾滋病与性传播感染

注射吸毒者中丙型肝炎病毒既往或现症感染的年龄相关差异:2015年美国8城市国家HIV行为监测

Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015.
PubMed 文献 · J Infect Dis · 2019-01-01

基于2015年美国8城市4094名注射吸毒者的监测数据,55.2%抗-HCV阳性,年轻(≤35岁)者42.1%,年长者(>35岁)62.2%。年轻者感染与教育程度低、接受性针具共享、共用注射器具、被捕史及注射speedball相关;年长者与教育程度低、共用器具、高注射频率及注射speedball相关。结论强调扩大直接抗病毒治疗、针具服务项目和药物辅助治疗。

要点

  • 注射吸毒者抗-HCV阳性率高达55.2%,年轻者42.1%,年长者62.2%。
  • 年轻者感染风险与接受性针具共享及注射speedball强相关。
  • 年长者感染风险与高注射频率及共用注射器具相关。

核心结论

  • 注射吸毒者中抗-HCV感染率很高且随年龄不同,需扩大直接抗病毒治疗、针具服务项目和药物辅助治疗以减轻传播风险和感染负担。

研究设计与样本

  • 基于2015年美国8城市国家HIV行为监测的横断面分析,纳入4094名注射吸毒者,计算调整患病率比(aPR)及95%置信区间(CI)。

主要发现

  • 4094名注射吸毒者中55.2%抗-HCV阳性;年轻(≤35岁)者阳性率42.1%,年长(>35岁)者62.2%。
  • 年轻者中,≤高中文凭/GED(aPR 1.17,95%CI 1.03-1.33)、接受性针具共享(aPR 1.37,95%CI 1.21-1.56)、共用注射器具(aPR 1.16,95%CI 1.01-1.35)、被捕史(aPR 1.14,95%CI 1.02-1.29)及注射speedball(aPR 1.37,95%CI 1.16-1.61)与抗-HCV阳性相关。
  • 年长者中,≤高中文凭/GED(aPR 1.08,95%CI 1.02-1.15)、共用注射器具(aPR 1.08,95%CI 1.02-1.15)、高注射频率(aPR 1.16,95%CI 1.01-1.34)及注射speedball(aPR 1.09,95%CI 1.01-1.16)与抗-HCV阳性相关。

临床怎么用

  • 对注射吸毒者应常规筛查抗-HCV,并根据年龄差异关注不同风险行为。
  • 针对年轻注射吸毒者重点干预接受性针具共享和speedball注射,年长者关注高频率注射和共用器具。
  • 应扩大直接抗病毒治疗、针具服务项目和药物辅助治疗的可及性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historically, older people who inject drugs (PWID) have had the highest hepatitis C virus (HCV) burden; however, young PWID now account for recent increases. We assessed factors associated with past or present HCV infection (HCV antibody [anti-HCV] positive) among young (≤35 years) and older (>35 years) PWID. METHODS: We calculated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) to examine sociodemographic and past 12-month injection behaviors associated with HCV infection. RESULTS: Of 4094 PWID, 55.2% were anti-HCV positive. Among young PWID, anti-HCV prevalence was 42.1% and associated with ≤high school diploma/General Education Development diploma (GED) (aPR, 1.17 [95% CI, 1.03-1.33]), receptive syringe sharing (aPR, 1.37 [95% CI, 1.21-1.56]), sharing injection equipment (aPR, 1.16 [95% CI, 1.01-1.35]), arrest history (aPR, 1.14 [95% CI, 1.02-1.29]), and injecting speedball (aPR, 1.37 [95% CI, 1.16-1.61]). Among older PWID, anti-HCV prevalence was 62.2% and associated with ≤high school diploma/GED (aPR, 1.08 [95% CI, 1.02-1.15]), sharing injection equipment (aPR, 1.08 [95% CI, 1.02-1.15]), high injection frequency (aPR, 1.16 [95% CI, 1.01-1.34]), and injecting speedball (aPR, 1.09 [95% CI, 1.01-1.16]). CONCLUSIONS: Anti-HCV prevalence is high among PWID and varies with age. Scaling up direct-acting antiviral treatment, syringe service programs, and medication-assisted therapy is critical to mitigating transmission risk and infection burden.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Abara WE, Trujillo L, Broz D, et al. Age-Related Differences in Past or Present Hepatitis C Virus Infection Among People Who Inject Drugs: National Human Immunodeficiency Virus Behavioral Surveillance, 8 US Cities, 2015. J Infect Dis. 2019. PMID: 30915477. doi:10.1093/infdis/jiz142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。